Zygolide brings first FDA-approved generic pergolide for PPID

Dechra’s Zygolide gives equine veterinarians a newly approved generic pergolide option for managing pituitary pars intermedia dysfunction in horses, a chronic endocrine disease better known to many pet parents as equine Cushing’s disease. The FDA announced on January 9, 2026, that it had approved Zygolide for control of clinical signs associated with PPID, calling it the first generic drug approved for this indication in horses. (fda.gov)

That matters because pergolide is already a mainstay of PPID treatment, but long-term management can be expensive, dose titration can be finicky, and daily administration can test adherence over months and years. FDA records show the reference listed drug is Boehringer Ingelheim’s Prascend, first approved in 2011. In the abbreviated approval, FDA concluded Zygolide is bioequivalent to Prascend based on an in vivo blood-level study in 24 healthy horses, supporting a generic entry rather than a new clinical standard. (fda.gov)

The product details line up closely with what equine clinicians would expect from pergolide therapy. According to the FDA freedom of information summary, Zygolide is a 1 mg prescription tablet indicated for oral use in horses, packaged in 60- or 160-tablet cartons, with a labeled starting dose of 2 mcg/kg once daily and dose adjustment up to 4 mcg/kg daily. Dechra’s marketing insert and The Horse promotional carousel add the commercial positioning: a peppermint-flavored tablet, a half-scored design intended to support dose accuracy, and messaging around consistent daily use. The carousel also leans heavily on owner-facing emotional language, including “Rediscover the partnership with Zyoglide” and “Help your horse feel their best so you can enjoy more happy moments together,” suggesting the launch is being framed not just around generic equivalence but around preserving quality of life in long-term PPID care. (animaldrugsatfda.fda.gov)

The approval also comes with the same clinical cautions veterinarians already associate with pergolide. FDA and Dechra materials warn that tablets should not be crushed because splitting or crushing pergolide can increase human exposure risk and may cause eye irritation, odor-related irritation, or headache. Reported adverse events in horses include anorexia, lethargy, weight loss, diarrhea, and colic, and Dechra’s insert notes that deaths, including euthanasia, have been reported in post-approval experience, though spontaneous reports do not establish causality. In the historical field effectiveness data referenced in the label, 76.1% of 113 evaluable horses were considered treatment successes at Day 180, and 41.6% required a dose increase at Day 90. (fda.gov)

Outside the approval documents, the broader equine endocrinology conversation helps explain why another pergolide option could get traction. Consensus-style recommendations and continuing education materials continue to place pergolide as first-line medical therapy for PPID, generally beginning around 2 mcg/kg and adjusting to clinical response and endocrine testing. Ongoing management often involves repeat ACTH monitoring and attention to appetite, attitude, laminitis risk, and concurrent insulin dysregulation. (aaep.org)

Industry reaction visible so far has been more practical than dramatic. The Horse promotional content frames Zygolide around partnership, consistency, and affordability, with one slide explicitly calling it “Cost-effective treatment” and citing Valley Vet pricing as of March 4, 2026. Online retail listings likewise suggest the market is already testing whether generic competition will shift price expectations for 160-count packs. I’d treat early retail pricing as directional rather than definitive, since pharmacy pricing can vary by channel and clinic markup, but the product is clearly being positioned as a more cost-conscious pergolide option. (thehorse.com)

Why it matters: For veterinary professionals, Zygolide may be most useful as a conversation tool as much as a prescription choice. In PPID, outcomes depend heavily on sustained daily therapy, follow-up testing, and pet parent buy-in. A generic, FDA-approved pergolide product with familiar dosing and administration may help practices address two common barriers at once: cost sensitivity and medication fatigue. It also gives clinicians an approved alternative to discuss when pet parents ask about compounded pergolide or struggle with long-term treatment budgets. Dechra’s launch messaging makes that strategy fairly plain: pair generic pricing claims with quality-of-life language that keeps the focus on maintaining the horse-owner relationship over time. (animaldrugsatfda.fda.gov)

What to watch: The next phase is commercial rather than scientific, including real-world pricing, clinic uptake, pet parent acceptance of the flavored and scored format, and whether generic competition changes prescribing patterns in senior horse medicine over the rest of 2026. It will also be worth watching whether the owner-directed themes in launch advertising, from “happy moments together” to “rediscover the partnership,” translate into stronger adherence and brand recognition in a category where treatment success depends on long-term consistency. (animaldrugsatfda.fda.gov)